The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
New research on the structure of HIV has revealed a promising novel drug target for treating HIV infection.
Today, we’re celebrating the clinical pharmacy specialist team at the William J. Holloway Community Program in Delaware.
The 2 most common, recommended, and simplified treatments for HCV are glecaprevir/pibrentasvir (Mavyret) and sofosbuvir/velpatasvir (Epclusa).
The widely available anti-parasitic drug ivermectin is capable of killing COVID-19 within 48 hours in a cell culture, according to a new study.
What would you recommend for these patients?
A study of the second HIV patient to undergo successful stem cell transplantation from donors with an HIV-resistant gene found that there was no active viral infection in the patient’s blood 30 months after they stopped antiretroviral therapy.
The findings highlight the critical role played by excess visceral adiposity in the progression of fibrosis among HIV-infected patients with nonalcoholic fatty liver disease, according to the study authors.
In addition, the new legislation calls for more intervention from local and state health officers, allowing them to recommend options ranging from testing to counseling. This includes the ability to mandate treatment for an individual determined to be placing others at risk.
Scientists at the Gladstone Institutes have cataloged host proteins that physically bind to HIV proteins, which identify human proteins that the virus can use to infect cells and spread.
The bill is intended to "prevent a health insurance carrier from requiring a covered person to undergo step therapy or to receive prior authorization before receiving HIV infection prevention drugs."
The Undectectable = Untransmittable (U=U) campaign started in early 2016 and has been sharing the message to dismantle the stigma surrounding HIV ever since. More than 970 community partners from 101 countries have come together to clear up the confusion about the science behind U=U.
Potential discrimination is at issue in a case against the insurer for mandating use of a specialty pharmacy.